Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Intravenous Chemotherapy and Plant-based Dietary Supplements

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Link salvestatakse lõikelauale
StaatusVärbamine
Sponsorid
Institut Cancerologie de l'Ouest

Märksõnad

Abstraktne

More and more patients report taking dietary supplements based on herbal medicine, aromatherapy, vitamintherapy,... in the course of their detoxifying anticancer chemotherapy, to stimulate the immune defenses, to relieve and/or decrease the side effects of chemo or even to act against cancer. At European level, there are between 15 and 73% of patients treated for cancer taking a dietary supplement (in particular phytotherapy) or a great heterogeneity according to the studies. However, there is still little evidence of the efficacy of these dietary supplements. A large proportion of patients do not seem to inform their doctor about the use of dietary supplements. Patients using dietary supplements most often ignore the mode of action of these products and generally say they are not informed.
In 2015, at the West Cancerology Institute (ICO), 5 patient files were analyzed taking this type of treatment in addition to chemotherapy; in 2016, 24 files; 2017, 61 patient records and this continues to progress.
At the same time, a product appears very frequently associated with cancer chemotherapy: Desmodium Adscendens, an African plant with in vitro properties of liver protector. The Desmodium contains triterpene saponins, alkaloids, flavonoids, polyphenols, and tryptamine derivatives.
Morevover, several situations of patients undergoing chemotherapy and taking long-term Desmodium, with hepatic cytolyses were experienced, not explained by the usual treatments (case described in the literature).
Therefore, this study will evaluate these new therapeutic modalities that are included in the intake of chemotherapy in order to better know them to improve the therapeutic taking of patients and to focus on the impact of Desmodium in association with chemotherapy.

Kirjeldus

- Determine the quantitative impact of the use of dietary supplements by patients with breast cancer and treated in a neo-adjuvant and/or adjuvant condition by IV chemotherapy in day hospital.

- Determine an over-risk of disruption of liver balance in the population of patients taking Desmodium.

- Gather a critical mass of relevant information with the objective of carrying out the evaluation and analysis of cancer care practices related to the intake of dietary supplements.

Kuupäevad

Viimati kinnitatud: 04/30/2019
Esmalt esitatud: 05/14/2019
Hinnanguline registreerumine on esitatud: 05/19/2019
Esmalt postitatud: 05/21/2019
Viimane värskendus on esitatud: 01/21/2020
Viimati värskendus postitatud: 01/22/2020
Õppe tegelik alguskuupäev: 04/01/2019
Eeldatav esmane lõpetamise kuupäev: 09/01/2020
Eeldatav uuringu lõpetamise kuupäev: 09/01/2020

Seisund või haigus

Breast Cancer

Sekkumine / ravi

Other: dietary supplements group

Faas

-

Käerühmad

ArmSekkumine / ravi
dietary supplements group
dietary supplements questionary
Other: dietary supplements group
Patient Questionary Patient to be carried out at the last cure

Abikõlblikkuse kriteeriumid

Õppimiseks sobivad vanused 18 Years To 18 Years
Uuringuks kõlblikud soodAll
ProovivõtumeetodNon-Probability Sample
Võtab vastu tervislikke vabatahtlikkeJah
Kriteeriumid

Inclusion Criteria:

- breast cancer treated by intra-venous chemotherapy

- inclusion at the last cycle (cure)

- all chemotherapy cycles realised at ICO

Exclusion Criteria:

- no breast cancer

- metastatic breast cancer

- not all chemotherapy cycles realised at ICO

- patient who has not finished his chemotherapy

Tulemus

Esmased tulemusnäitajad

1. evaluate quantitatively the use of dietary supplements in patients during IV chemotherapy [12 months]

rate of patients taking a dietary supplement

Sekundaarsed tulemusmõõdud

1. Evaluate the impact of taking Desmodium between the first and last cycle of treatment [12 months]

% of patients with hepatic cytolysis undergoing chemotherapy between the first and last treatments

2. Description of dietary supplements taken [12 months]

Description of different types of dietary supplements

Liitu meie
facebooki lehega

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus

  • Töötab 55 keeles
  • Taimsed ravimid, mida toetab teadus
  • Maitsetaimede äratundmine pildi järgi
  • Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
  • Lugege oma otsinguga seotud teaduspublikatsioone
  • Otsige ravimtaimi nende mõju järgi
  • Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega

Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel

Google Play badgeApp Store badge